NCT01030679

Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus

To Investigate the Glycemic Control and Lipid Profile of CKD-501 Monotherapy in Patients With Type 2 Diabetes Mellitus:a Eight-week, Multicenter, Randomized, Double-blind, Parallel-Group, Placebo-controlled, Dose-ranging Study.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 214 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety and effectiveness of three doses of CKD-501 compared to placebo in lowering fasting plasma glucose levels in people with type 2 diabetes for 8 weeks.

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	CKD-501 0.5mg	0.5 mg/tablet, orally, 1 tablet once daily for 8 weeks
DRUG	CKD-501 1mg	1 mg/tablet, orally, 1 tablet once daily for 8 weeks
DRUG	CKD-501 2mg	2 mg/tablet, orally, 1 tablet once daily for 8 weeks
DRUG	Placebo	orally, 1 tablet once daily for 8 weeks

Timeline

• Start date: 2007-07-01
• Primary completion: 2008-10-01
• Completion: 2008-10-01
• First posted: 2009-12-11
• Last updated: 2009-12-16

Locations

8 sites across 1 country: South Korea